Hua Medicine has announced the first innovative diabetes drug, Dozaglietin. (Dorzagliatin's NDA application was accepted by the National Medical Products Administration's (NMPA) Center for...
Compared to the placebo group, patients with diabetes who received 54 weeks of treatment had higher levels of endogenous insulin secretion with no safety...